Meet
Samantha Ferguson

Sam Ferguson supports clients in market access, product commercialization, and reimbursement strategy.

She applies her experience in international health policy to help clients successfully navigate the U.S. health market and optimize product access and delivery.

Prior to joining Avalere, Sam was a senior program associate with Results for Development, where she focused on helping countries achieve universal health coverage. There, she applied collaborative learning and capacity-building approaches to strengthen healthcare institutions for independent and sustainable progress. Additionally, Sam serves as a board member for RightAnswer, a chemical safety and knowledge management solution startup.

Sam holds a BA in biochemistry and dance from Oberlin College.

Authored Content


As treatment advancements in oncology continue, stakeholders are modifying their approaches to defining value and managing care

In this third episode, Sam Ferguson, a consultant in Avalere’s Market Access practice, along with Allison Petrilla, a managing director in Avalere’s Health Economics and Advanced Analytics practice, and Amy Schroeder, a senior consultant in Avalere’s Market Access practice, discuss how stakeholders are utilizing and translating real-world evidence (RWE) into value for oncology.

In the second episode, Sam Ferguson and Michael Kearney, consultants in Avalere’s Market Access practice, along with Megan Olsen, an associate principal in Avalere’s Policy practice, will discuss how to appropriately define the value of durable therapies in oncology and how to pay for those therapies within our current healthcare system.

In the first episode, Sam Ferguson and Biruk Bekele, consultants in Avalere’s Market Access practice, along with Milena Sullivan, a principal in Avalere’s Policy practice, will discuss how stakeholders are defining value in oncology.

Recent Avalere analysis finds decreases in utilization of oncology and autoimmune treatments across all care settings since the onset of the health crisis.

Oncology practices with a substantial proportion of Oncology Care Model (OCM) episodes in areas with high numbers of COVID-19 cases—such as Connecticut, Louisiana, Massachusetts, New Jersey, New York, and Pennsylvania—may face new challenges in containing total expenditure below target amounts.

ICER is eager to position itself as the primary comparative and cost-effectiveness research body in the US. While their activity has been traditionally more limited to product-specific reviews, the Institute is increasingly looking to shape the broader debate around value and drug pricing.

Avalere experts published a supplement in the June 2019 American Journal of Managed Care entitled “Ensuring Appropriate Access to Pulmonary Arterial Hypertension Therapy.”

Beginning in 2019, CMS will reimburse for 5 codes relating to virtual care delivery and remote monitoring